Table1_Clinical significance of regional constructive and wasted work in patients receiving cardiac resynchronization therapy.docx

BackgroundPrevious studies have shown that global constructive work (CW) and wasted work (WW) predict response to cardiac resynchronization therapy (CRT). This study evaluated the predictive value of regional CW and WW for reverse remodeling and clinical outcomes after CRT.MethodsWe performed a prospective study involving 134 CRT candidates with left bundle branch block and left ventricular ejection fraction ≤35%. Global and regional CW and WW were calculated using pressure-strain loop analysis. CRT response was defined by reverse remodeling as a reduction of ≥15% in left ventricular end-systolic volume after six months.ResultsAt six-month follow-up, 92 (69%) patients responded to CRT. Of the regional CW and WW measures, lateral wall (LW) CW and septal WW were most strongly and significantly correlated with reverse remodeling. At multivariate analysis, LW CW and septal WW were both independent determinants of reverse remodeling. When LW CW and septal WW were included in the model, global CW and WW were not independently associated with reverse remodeling. LW CW and septal WW predicted reverse remodeling with an area under the curve (AUC) of 0.783 (95% CI: 0.700–0.866) and 0.737 (95% CI: 0.644–0.831), respectively. Using both variables increased the AUC to 0.832 (95% CI: 0.755–0.908). Both LW CW ≤878 mmHg% (HR 2.01; 95% CI: 1.07–3.79) and septal WW ≤181 mmHg% (HR 2.60; 95% CI: 1.38–4.90) were significant predictors of combined death and HF hospitalization at two-year follow-up.ConclusionLW CW and septal WW before CRT are important determinants of reverse remodeling and clinical outcomes.</p

MOESM1 of Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Additional file 1: Table S1. International Classification of Disease (9th edition) Clinical Modification (ICD 9-CM) codes used to define the co-morbidities and clinical outcome in the study cohort

MOESM1 of Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Additional file 1: Table S1. International Classification of Disease (9th edition) Clinical Modification (ICD 9-CM) codes used to define the co-morbidities and clinical outcome in the study cohort

MOESM2 of Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Additional file 2: Figure S1. Cumulative risk curve of the new-onset AF for the study cohorts treated with metformin plus DDP-4 inhibitor or other hypoglycemic agents before propensity score weighting. DDP4i group (solid line) had a significantly lower cumulative risk of new-onset AF compared with non-DDP4i group in patients treated with metformin (dotted line). DPP4i dipeptidyl peptidase-4 inhibitor